Quantification of intracellular proteins and monitoring therapy using flow cytometry

Current Drug Targets

Volumn 11, Issue 8, 2010, Pages 994-999

  Chang, Richard L ^a   Yeh, Chen Hsiung ^a   Albitar, Maher ^a  

^a QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

Author keywords

Drug discovery; Multiparameter; Quantitative flow cytometry; Targeted therapy

Indexed keywords

CELL MARKER; CELL PROTEIN; PHYCOERYTHRIN; BIOLOGICAL MARKER; SIGNAL PEPTIDE;

ANTIBODY SPECIFICITY; ARTICLE; AUTOMATION; CALIBRATION; CELL MEMBRANE PERMEABILITY; CELL POPULATION; CELL SURFACE; CELL TYPE; CONJUGATION; FLOW CYTOMETRY; FLUORESCENCE; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOHISTOCHEMISTRY; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RELIABILITY; SIGNAL TRANSDUCTION; TARGET CELL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG MONITORING; METABOLISM; METHODOLOGY; REVIEW;

BIOLOGICAL MARKERS; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; DRUG MONITORING; FLOW CYTOMETRY; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PHYCOERYTHRIN;

EID: 77956892628     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945010791591296     Document Type: Article

References (33)

1. Krutzik PO, Irish JM, Nolan GP, Perez OD. Analysis of proteinphosphorylation and cellular signaling events by flow cytometry:techniques and clinical applications. Clin Immunol 2004; 110: 206-21.
2. Chan HH, Jilani I, Chang R, Albitar M. Monitoring cell signaling pathways by quantitative flow cytometry. Methods Mol Biol 2007;378: 83-90.
3. David K.A., Abrams B., Hoffman R.A., Bishop J.E. Quantitation and valence of antibodies bound to cells. Cytometry 1996; Suppl 8:AC150.
4. Wang L, Gaigalas AK, Marti G, Abbasi F, Hoffman RA. Towardquantitative fluorescence measurements with multicolor flowcytometry. Cytometry Part A 2007; 73A: 279-88.
5. Krutzik PO, Crane JM, Clutter MR, Nolan GP. High-contentsingle-cell drug screening with phosphospecific flow cytometry. Nat Chem Biol 2008; 4: 132-42.
6. Sklar LA, Carter MB, Edwards BS. Flow cytometry for drugdiscovery, receptor pharmacology and high-throughput screening. Curr Opin Pharmacol 2007; 7: 527-34.
7. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancertherapy. N Engl J Med 2005; 353: 172-187.
8. Wong S, Witte ON. The BCR-ABL story: bench to bedside andback. Annu Rev Immunol 2004; 22: 247-306.
9. Chan LC, Karhi KK, Rayter SI, et al. A novel abl protein expressedin Philadelphia chromosome positive acute lymphoblasticleukaemia. Nature 1987; 325: 635-7.
10. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance toSTI-571 cancer therapy caused by BCR-ABL gene mutation oramplification. Science 2001; 293: 876-80.
11. Druker BJ. STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol Med 2002; 8: S14-S18.
12. Rosée PL, Holm-Eriksen S, Konig H, et al. Phospho-CRKLmonitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblasticleukemia patients treated with nilotinib. Haematologica 2008; 93:765-769.
13. Bhat A, Kolibaba K, Oda T, et al. Interactions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed Myeloid Cells. J BiolChem 1997; 272: 16170-16175.
14. Yu H, Jove R. The STATs of cancer--new molecular targets comeof age. Nat Rev Cancer 2004; 4: 97-105.
15. Moriggl R, Sexl V, Kenner L, et al. Stat5 tetramer formation isassociated with leukemogenesis. Cancer Cell 2005; 7: 87-99.
16. Jacobberger JW, Sramkoski RM, Frisa PS, et al. Immunoreactivityof Stat5 phosphorylated on tyrosine as a cell-based measure ofBcr/Abl kinase activity. Cytometry A 2003; 54: 75-88.
17. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKTpathway in human cancer. Nat Rev Cancer 2002; 2: 489-501.
18. Wolffe AP, Hayes JJ. Chromatin disruption and modification.Nucleic Acids Res 1999; 27: 711-720.
19. Legube G, Trouche D. Regulating histone acetyltransferases anddeacetylases. EMBO Rep 2003; 4: 944-947.
20. Ropero S, Esteller M. The role of histone deacetylases (HDACs) inhuman cancer. Mol Oncol 2007; 1: 19-25.
21. Secrist JP, Zhou X, Richon VM. HDAC inhibitors for the treatmentof cancer. Curr Opin Invest Drugs 2003; 4: 1422-1427.
22. Hidalgo M., Rowinsky E.K. The rapamycin-sensitive signaltransduction pathway as a target for cancer therapy. Oncogene 2000; 19: 6680-6686.
23. Rowinsky EK. Targeting the molecular target of rapamycin(mTOR). Curr Opin Oncol 2004; 16: 564-75.
24. Vignot S, Faivre S, Aguirre D, Raymond E. MTOR-targetedtherapy of cancer with rapamycin derivatives. Ann Oncol 2005; 16:525-537.
25. Krutzik PO, Nolan GP. Fluorescent cell barcoding in flowcytometry allows high-throughput drug screening and signalingprofiling. Nat Methods 2006; 3: 361-368.
26. Du J, Li M, Zhang D, et al. Flow cytometry analysis of glucocor-ticoid receptor expression and binding in steroid-sensitive andsteroid-resistant patients with systemic lupus erythematosus.Arthritis Res Ther 2009; 11: R108. (doi:10.1186/ar2763).
27. Towers R, Naftali T, Gabay G, et al. High levels of glucocorticoidreceptors in patients with active Crohn's disease may predict steroidresistance. Clin Exp Immunol 2005; 141: 357-362.
28. Kay S, Herishanu Y, Pick M, et al. Quantitative flow cytometry ofZAP-70 levels in chronic lymphocytic leukemia using molecules ofequivalent soluble fluorochrome. Cytometry B 2006; 70: 218-226.
29. Pedreira CE, Costa ES, Almeida J, et al. ZAP-70 in CLL: towardsstandardization of a biomarker for patient management: history ofclinical cytometry. Cytometry A 2008; 73: 1141-1150.
30. Green LJ, Marder P, Ray C, et al. Development and validation of adrug activity biomarker that shows target inhibition in cancerpatients receiving enzastaurin, a novel protein kinase C-betainhibitor. Clin Cancer Res 2006; 12: 3408-3415.
31. Jilani I, Kantarjian H, Gorre M, et al. Phosphorylation levels ofBCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronicmyeloid leukemia cells implicate alternative pathway usage as asurvival strategy. Leukemia Res 2008; 32: 643-649.
32. Hamilton A., Elrick L., Myssina S., et al. BCR-ABL activity and itsresponse to drugs can be determined in CD34_ CML stem cells byCrkL phosphorylation status using flow cytometry. Leukemia 2006; 20: 1035-1039.
33. Groselj-GrencM., IhanA., Derganc M. Neutrophil and MonocyteCD64 and CD163 Expression in critically Ill neonates and childrenwith sepsis: comparison of fluorescence intensities and calculatedindexes. Mediators Inflamm 2008; Hindawi Publishing Corpo-ration. Article ID 202646, 10 pages. (doi:10.1155/2008/ 202646)